Capricor Therapeutics Inc (CAPR) Stock News

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements regarding changes to its statistical analysis plan for the Deramiocel drug candidate without FDA approval. The FDA's briefing documents revealed concerns about the integrity of the clinical data analysis, leading to a 64% stock price decline on July 27, 2026, followed by a 36% decline after an advisory committee voted against the drug's efficacy on July 29, 2026.

A class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA agreement, creating significant regulatory approval risks. Investors who purchased during this period may be entitled to compensation.

Rosen Law Firm has filed a class action lawsuit against Capricor Therapeutics (CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA approval, creating significant regulatory risk for the cell therapy's approval for treating Duchenne muscular dystrophy. Investors must move the court by September 28, 2026 to serve as lead plaintiff.

A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 6, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing securities to trade at artificially inflated prices. Investors who suffered losses are encouraged to contact the law firm or submit claims by September 28, 2026 to potentially serve as lead plaintiff.

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its lead drug candidate Deramiocel. The FDA rejected the drug application after discovering undisclosed changes to the statistical analysis plan, causing Capricor's stock to plummet 64% on July 27, 2026, and an additional 36% on July 29, 2026, following an advisory committee vote against the drug's efficacy.

The FDA announced that Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of its Phase 3 trial, contradicting the company's claims from the previous year. Following this disclosure, Capricor's stock price declined significantly.

Law firm Lowey Dannenberg is investigating Capricor Therapeutics for potential federal securities violations following disclosure that FDA briefing materials relied on an outdated statistical analysis plan for its Deramiocel therapy BLA. The stock fell 64% after the disclosure, and an FDA Advisory Committee subsequently voted against the drug's effectiveness for cardiomyopathy in DMD patients.

The FDA released briefing materials on July 27, 2026, raising concerns about Capricor Therapeutics' deramiocel cell therapy for treating cardiomyopathy associated with Duchenne muscular dystrophy. The FDA's advisory panel voted 9-3 against the therapy, citing insufficient evidence of effectiveness and concerns that the company changed how it measured trial results. Following the announcement, Capricor's stock price plummeted approximately 67% on July 29, 2026, and fell another 50% in premarket trading on July 30, 2026.

Hagens Berman has opened an investigation into Capricor Therapeutics following a 64% stock collapse on July 27, 2026. The FDA's briefing document revealed that the company's lead drug candidate Deramiocel failed to meet pre-specified primary and secondary efficacy endpoints in the Phase 3 HOPE-3 trial, contradicting Capricor's December 2025 announcement of 'positive' results. The investigation focuses on whether Capricor misled investors about trial efficacy and undisclosed changes to the statistical analysis plan.

The FDA announced that Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of its Phase 3 trial, contradicting the company's claims from the previous year. Following this disclosure, Capricor's stock price declined significantly.

Dimensional Fund Advisors Ltd. has disclosed a 3.48% stake in Capricorn Energy PLC, comprising 2,456,626 ordinary shares as of June 25, 2026. The disclosure includes a sale of 2,833 shares at 2.8166 GBP per unit. Dimensional acts as an investment advisor and disclaims beneficial ownership of the shares.

Dimensional Fund Advisors Ltd. has disclosed a 3.57% stake in Capricorn Energy PLC as of May 28, 2026, comprising 2,521,781 ordinary shares. The disclosure includes recent sales transactions totaling 3,230 shares at prices of 3.2300 GBP and 3.2151 GBP per unit. Dimensional, an investment advisor, expressly disclaims beneficial ownership and notes it lacks discretion over 10,183 of the disclosed shares.